Tenofovir (all routes except local)

Child/Infant lenght abnormalities (> 1 year)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5160
R13458		 Pintye, 2015 9-month z-scores for length-for-age (LAZ) < −2 SD during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: Yes Control group: zidovudine/lamivudine/nevirapine Exposed group: TDF/lamivudine-based Indication: HIV 1.89 [0.80;4.46] 14/38   22/84 36 38
ref
S5124
R13307		 Siberry, 2012 Short length at one year (gestation- or age-adjusted z-score< −1.5) during pregnancy (anytime or not specified) cohort exposed to other treatment, sick Adjustment: Yes Control group: non-TDF (mix or unspecified regimens) Exposed group: TDF (mix or unspecified regimens) Indication: HIV 0.95 [0.50;1.79] 17/217   30/368 47 217
ref
Total 2 studies 1.26 [0.65;2.44] 83 255
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Pintye, 2015Pintye, 2015 1.89[0.80; 4.46]363841%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Siberry, 2012Siberry, 2012 0.95[0.50; 1.79]4721759%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 37% 1.26[0.65; 2.44]832550.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.26[0.65; 2.44]8325537%NAPintye, 2015 Siberry, 2012 2 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 1.26[0.65; 2.44]8325537%NAPintye, 2015 Siberry, 2012 2 Tags Adjustment   - Yes  - Yes 1.26[0.65; 2.44]8325537%NAPintye, 2015 Siberry, 2012 2 Control group   - non-TDF (mix or unspecified regimens)  - non-TDF (mix or unspecified regimens) 0.95[0.50; 1.80]47217 -NASiberry, 2012 1   - zidovudine/lamivudine/nevirapine  - zidovudine/lamivudine/nevirapine 1.89[0.80; 4.46]3638 -NAPintye, 2015 1 Exposed group   - TDF (mix or unspecified regimens)  - TDF (mix or unspecified regimens) 0.95[0.50; 1.80]47217 -NASiberry, 2012 1   - TDF/lamivudine-based  - TDF/lamivudine-based 1.89[0.80; 4.46]3638 -NAPintye, 2015 1 Indication   - HIV  - HIV 1.26[0.65; 2.44]8325537%NAPintye, 2015 Siberry, 2012 2 All studiesAll studies 1.26[0.65; 2.44]8325537%NAPintye, 2015 Siberry, 2012 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.26[0.65; 2.44]8325537%NAPintye, 2015 Siberry, 2012 20.510.01.0